Blade Therapeutics | Revolutionizing the Treatment of Fibrotic Disease

Discovering breakthroughs in fibrosis and neurodegeneration

Discovering breakthroughs in fibrosis and neurodegeneration

Discovering breakthroughs in fibrosis and neurodegeneration

Pipeline

We are positioned to build a pipeline across a range of fibrotic and neurodegenerative diseases.

Cudetaxestat
(Lung Fibrosis)

Phase 2
Ready

BLD-2184
(Neurodegeneration)

IND Ready

BLD-3051
(Lung Fibrosis, Liver Fibrosis)

Pre-Clinical

Join our team

We are looking for people with the passion and commitment of the values we live by.

Passion and commitment to our mission

Accountability to the team

Integrity in everything we do

Be fearless

Recent News

January 12, 2022

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

November 30, 2021

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

November 18, 2021

Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development

Event

There are no events currently scheduled.

Bringing life changing and revolutionary treatments to patients with fibrotic and neurodegenerative diseases.